Apheris
CompanyAI is fundamentally dependent on data, but the vast majority of health data goes unused for understandable reasons — chiefly patient privacy, regulation, and IP protection. “This is the core underlying problem” of building AI solutions for life sciences and related areas like pharmaceutics, said German entrepreneur Robin Röhm.
Date
Jan 2, 2025
Category
devtools
Lead investor
OTB Ventures
Stage
Series A
Size
$20.8M
Bain Capital Ventures
Matrix Partners
Next47
a16z
Khosla Ventures
Decibel Partners
Greylock
Theory Ventures
Lerer Hippeau
HV Capital
Accel
FinTech Collective